Innovating Works

ALMAC

Desconocido
TransPot: Translational Research Network in Prostate Cancer ALMAC DIAGNOSTIC SERVICES LIMITED participó en un H2020 H2020-MSCA-ITN-2016 The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly...
2016-08-16 - 2021-04-30 | Financiado
TRACT: Training in Cancer Mechanisms and Therapeutics ALMAC DIAGNOSTIC SERVICES LIMITED participó en un H2020 H2020-MSCA-ITN-2016 The European community requires early stage researchers (ESRs) trained in next-generation technologies for improved detection and treatment...
2016-08-11 - 2020-09-30 | Financiado
INFLA-CARE: Understanding inflammation associated tumorigenesis for the rational design of novel anti cancer the... ALMAC DIAGNOSTIC SERVICES LIMITED participó en un FP7 Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cell...
Financiado
HELICOVAXOR: Development of an oral Helicobacter Pylori vaccine ALMAC DIAGNOSTIC SERVICES LIMITED participó en un FP7 Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly...
Financiado
MABSOT: Development of OPN 305 as an orphan drug for the treatment of Delayed Graft Function post solid orga... ALMAC DIAGNOSTIC SERVICES LIMITED participó en un FP7 Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejectio...
Financiado
BIOMARKERIGF: Identification of Clinically Useful Biomarkers for IGF I Receptor Signalling n Cancer ALMAC DIAGNOSTIC SERVICES LIMITED participó en un FP7 The Insulin-like Growth Factor I Receptor (IGF-IR) is widely expressed on human tissues and has been shown to promote the growth and invasiv...
Financiado
ENDOPREDICT: Protein biomarker for the prediction of response to endocrine treatment in breast cancer patients ALMAC DIAGNOSTIC SERVICES LIMITED participó en un FP7 Classical pathologic parameters have been used to inform adjuvant clinical treatment choices for early breast cancer patients. There remain...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.